- Company
- Reimb approval JAKi switching can change RA treatment in KOR
- by Son, Hyung Min Mar 7, 2025 05:56am
- “The realistic goal for treating rheumatoid arthritis is remission, not cure. With various treatment options introduced for the disease, patients can expect good results if they start treatment by administering the right treatment for them. In particular, since switching is now allowed for oral treatment options like JAK inhibitors, this ma
- Company
- Roche adds expertise through leadership appointments
- by Whang, byung-woo Mar 7, 2025 05:56am
- Roche Korea is strengthening its leadership by appointing new leads to its Oncology and Hematology cluster and Specialty Medicines cluster. The company announced on the 5th that it has appointed Jinyoung Jeong as the new head of the Oncology·Hematology Cluster and Hyun-mi Kim as the new head of the Specialty Medicines Cluster. By appo
- Company
- SK Chemical signs a joint sales agreement with Viatris
- by Lee, Seok-Jun Mar 6, 2025 05:58am
- SK Chemicals, which developed the first natural drug for osteoarthritis in Korea, ‘Joins Tab,’ has secured additional pain medications for its portfolio. SK Chemical (CEO Jae-Hyun Ahn) announced on the 5th that it has signed a distribution and sales agreement with Viatris Korea for △Lyrica, △ Neurontin, and △ Celebrex. Under the
- Company
- Vyndamax is reimbursed for ATTR-CM in Korea
- by Whang, byung-woo Mar 6, 2025 05:58am
- Pfizer Korea announced on the 5th that its Vyndamax (tafamidis), a treatment for wild-type or hereditary transthyretin amyloidosis cardiomyopathy (ATTR-CM), has been granted reimbursement by Korea’s National Health Insurance. ATTR-CM is a progressive rare disease in which the naturally circulating transport protein in the blood, transthy
- Company
- Novo Nordisk Korea appoints Kasper Roseeuw Poulsen as new GM
- by Whang, byung-woo Mar 6, 2025 05:58am
- On March 5, Novo Nordisk Korea announced the appointment of Kasper Roseeuw Poulsen as the new General Manager starting March 2025. The new GM Kasper Roseeuw Poulsen joined Novo Nordisk in 2006 and served key roles in finance, strategy, organizational development, commercial partnership, and management across Europe, South America, and Asi
- Company
- Pfizer launches JAK inhibitor for severe alopecia areata
- by Whang, byung-woo Mar 6, 2025 05:58am
- Pfizer Korea will launch a new Janus kinase (JAK) inhibitor treatment Litfulo (ritlecitinib tosilate), and set to challenge the market for severe alopecia areata. Previously launched Olumiant (baricitinib), the first drug approved in South Korea for treating adult patients with severe alopecia areata, has already settled in the market. The co
- Company
- "COVID-19 response has changed to protect high risk groups"
- by Whang, byung-woo Mar 5, 2025 06:01am
- As COVID-19 transitioned to the endemic phase, an important issue has arisen regarding 'how' to prevent and respond to the disease, unlike the initial period focused only on response. One of the big changes was the reimbursement of treatments. On October 25, 2024, The Ministry of Health and Welfare (MOHW) approved the National Health Insuranc
- Company
- Ocrevus is reimbursed for relapsing multiple sclerosis
- by Whang, byung-woo Mar 5, 2025 06:00am
- On March 4, Roche Korea announced that its multiple sclerosis treatment drug Ocrevus (ocrelizumab) will be reimbursed by Korea’s National Health Insurance from March 1. According to the new announcement, Ocrevus will be covered as a monotherapy for patients with relapsing multiple sclerosis, which includes ▲patients with relapsing-remit
- Company
- Pfizer’s sales fall 76% in 2 yrs with the end of pandemic
- by Son, Hyung Min Mar 5, 2025 06:00am
- Pfizer Korea’s sales are on a downward trend. The company's sales have plummeted by 76% in 2 years. The analysis is that the demand for COVID-19 vaccines and treatments has fallen sharply, which has affected the decline in sales. Pfizer Korea aims to make a rebound in sales with new products such as Prevnar 20, a new pneumococcal vaccine, a
- Company
- Reimbursement possible for Long-acting HIV treatment in KOR
- by Whang, byung-woo Mar 4, 2025 05:57am
- Expectations are growing in the clinical field with the imminent reimbursement of the long-acting HIV (human immunodeficiency virus) treatment ‘Vocabria+Rekambys’ combination in Korea. It has been more than two years since the combination was approved in Korea, but it has not yet been released on the market due to hurdles including costs.
